



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-Human Cytokeratin 8 [1E8-C6-B4] Standard Size Ab02687-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: 1E8-C6-B4

Alternative Name(s) of Target: K8; Cytokeratin 8; CK 8; 1E8; Keratin, type II cytoskeletal 8; Keratin-8; Type-II keratin Kb8; 1E8

UniProt Accession Number of Target Protein: P05787

Published Application(s): WB, IP, IF

Published Species Reactivity: Human

Immunogen: The original antibody was generated by immunizing mice against the C-terminus (amino acids 472-483) of human Cytokeratin 8.

Specificity: The antibody is specific for the C-terminus of cytokeratin 8, one member of a diverse group of proteins called intermediate filament proteins. These proteins are often expressed in pairs. Cytokeratin 8 pairs with Cytokeratin 18 to form a component of the cytoskeleton in simple epithelial cells. Cytokeratin 8 is present on the surface of intact hepatocytes, hepatocellular carcinoma cells, and breast cancer cells.

Application Notes: The original antibody detected CK 8 by western blot from BT20 breast cancer cells. Immunofluorescence was performed on BT20 cells using this antibody, showing the carboxyl terminus of CK 8 was exposed on the surfaces of breast cancer cells. The Fab fragment of the antibody was used for inhibition experiments on breast cancer cell lines BT20, MDA-MB-157, MCF-7 and purified CK 8. Results showed a decreased plasminogen binding in all the experiments. The Fab fragment was used to study the role of cell-surface CK 8 in promoting the activation of plasminogen by t-PA in MCF-7 cells; preincubation of MCF-7 cells with the Fab fragment caused a concentration-dependent decrease in the ability of the cell cultures to promote plasminogen activation (Hembrough et al, 1996; pmid:8810346).

Antibody First Published in: Hembrough et al. Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator J Biol Chem. 1996 Oct 11;271(41):25684-91.

[PMID:8810346](#)

Note on publication: The paper describes the generation and characterization of an antibody against cytokeratin 8 for the purpose of defining its immunological, cellular, and biochemical characteristics.

Product Form

Size: 200 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.